Goldman Sachs Group, Inc. (GS), Morgan Stanley (MS): Investment Banking Winners & Losers in Early 2013

Page 1 of 2

There is no industry more wild, crazy, or fun to look at then those specializing in investment banking. This ultimate cyclical industry has become a tad less cyclical when many of the remaining large players became banks in order to qualify for government bailouts in the troubled times late last decade. As banks, and subject to higher regulatory scrutiny and capitalization rules, earnings have moderated their erratic swings somewhat. I am focusing today solely on companies whose revenue focus is trading market making and underwriting. Some large commercial banks, especially JPMorgan Chase & Co. (NYSE:JPM)Citigroup Inc. (NYSE:C) and Bank of America Corp (NYSE:BAC) have investment banking arms, but those sorts of institutions are not today’s focus.

Goldman Sachs (GS)By most measures, Goldman Sachs Group, Inc. (NYSE:GS) is the largest investment bank in the country. Over the past ten years, annual revenues have ranged from a high of about $88 billion to a low of $23 billion, and profits have ranged from over $13 billion to just over $2 billion. 2012 turned out to be a good, yet not a great year. The second half of the year was boosted with a number of large debt issues, as many are leery that long term debt rates will hold at this low rate forever.

Largely as a result of this increased activity, along with a strong stock market, Goldman Sachs reported fourth quarter 2012 earnings of $2.9 billion, or $5.60 per share, swamping analysts’ expectations of $3.66 per share, and roughly tripling the $1.84 per share reported in the fourth quarter of 2011. For all of 2012, earnings came to $7.5 billion, or $14.13 per share, nearly tripling the 2011 total. The 2012 profit represented a 10.7% return on shareholders’ equity, which while substantially better than 2011′s 6.3%, hardly compares to the 25% or more return on equity achieved during Goldman Sachs Group, Inc. (NYSE:GS)’ salad days six to eight years ago. That return on equity ratio is important to management, as bonuses are tied into increasing that profitability measure. Due to increased regulatory scrutiny from Goldman Sachs being a bank, those days of 20% – plus returns on equity are likely a thing of the past.

Looking into 2013, continued uncertainty in the domestic economy, along with deepening malaise in Europe do not bode well. Goldman Sachs stock price is up some 35% over the past year, and is touching 52 week highs as I write this. I agree with analysts who see earnings more or less treading water for the next couple years, and I believe the stock has gotten ahead of itself a little bit. Goldman Sachs is the premier company in the investment banking niche, but with its 1.65 PEG it hardly excites me at this price and absent a pull back to 120 or below, I would not be a buyer of Goldman Sachs.

Morgan Stanley (NYSE:MS) has a much better PEG than its larger rival, at 0.58. It also has a slightly more optimistic analyst rating, at 2.5 compared with Goldman Sachs’ 2.7. But a lot of that profit growth is coming on the heels of relatively depressed 2012 annual earnings of $0.13 per share. The reason for that low PEG is that from the depressed profit levels of 2012, Morgan Stanley (NYSE:MS) has nowhere to go but up.

How far up can we expect Morgan Stanley to go, earnings wise, over the next year or two? One thing is that this big investment bank has been hemorrhaging DVA adjustments in recent quarters. Those should even out as the economy shows signs of growth and interest margins spread. But as for earnings from operations, Morgan Stanley is more reliant on the North American economy than is Goldman Sachs, and I do not see a huge upsurge in domestic investment banking activity going forward. With the stock price up 30% over the past year, I don’t see much upside for the stock price. I am inclined to pass on Morgan Stanley as well.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!